Actively Recruiting
Home-based Heat Therapy for Type 2 Diabetes
Led by Montreal Heart Institute · Updated on 2026-05-12
44
Participants Needed
1
Research Sites
301 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Insulin resistance and hyperglycemia predispose individuals with type 2 diabetes mellitus (T2DM) to endothelial dysfunction and a greater risk of cardiovascular diseases (CVD). Increased CVD risk in individuals with T2DM persists despite optimal pharmacological therapy, highlighting the need to identify complementary lifestyle interventions that improve cardiometabolic functions in this population. Evidence from animal models suggests that heat exposure improves metabolic functions. Notably, weekly heat exposure for 16 weeks blunts hyperinsulinemia and hyperglycemia induced by a high fat diet in mice. In parallel, studies in humans have shown that heat exposure improves vascular endothelial function. Based on such findings, it has been suggested that heat therapy may represent an effective lifestyle intervention to improve cardiometabolic functions. However, only 1 study has examined the impact of a heat therapy intervention on individuals with T2DM, demonstrating that 6 weeks of heat exposure reduces fasting plasma glucose and hemoglobin A1C. No study has considered potential vascular benefits of heat therapy in individuals with T2DM. This project will investigate cardiometabolic responses to repeated heat exposure in men and women with T2DM. We will test the hypothesis that 12 weeks of heat therapy improves postprandial fatty acid handling, insulin sensitivity and endothelial function in individuals with T2DM.
CONDITIONS
Official Title
Home-based Heat Therapy for Type 2 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 45 to 75 years
- Diagnosis of type 2 diabetes mellitus for at least 1 year
- Stable medication regimen for at least 12 weeks
You will not qualify if you...
- Class 3 obesity
- Hypertension not controlled by medication
- Diagnosis of cardiac, renal, or pulmonary disease
- Severe neuropathy and/or retinopathy
- Use of insulin therapy
- Fasting plasma triglycerides greater than 5.0 mmol/L
- Fasting total cholesterol greater than 7 mmol/L
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre ÉPIC, Montreal Heart Institute
Montreal, Quebec, Canada, H1T1N6
Actively Recruiting
Research Team
D
Daniel Gagnon, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here